LB Pharmaceuticals Inc (LBRX)
LBRX moved a median of -0.68% 30 minutes after news, and -0.77% by the close. How LBRX actually reacts to news — the realized, point-in-time move the market made, measured across 135 labeled events over the last three years with zero look-ahead.
LBRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 134 |
| 30-min | -0.68% | 31% | 135 |
| 60-min | -1.22% | 37% | 135 |
| to close | -0.77% | 38% | 133 |
| Middle 50% of LBRX reactions | -2.20% to +0.65% |
|---|---|
| Median reaction (30-min) | -0.68% |
| Measured reactions | 135 |
Half of all LB Pharmaceuticals Inc news events land between -2.20% and +0.65% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LBRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 24 | -1.63% | 38% | -1.18% |
| Rating reiterations | 14 | -0.55% | 36% | +0.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how LBRX ranks against every other measured name →
That’s how LBRX usually reacts — get an email when it moves on news →Email me when LBRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LBRX's baseline. Nothing else.
Recent LBRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| LB Pharmaceuticals to Participate in Upcoming Investor Events | Press release | GlobeNewswire | +0.08% | +0.33% | |
| LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress | Press release | GlobeNewswire | -3.14% | -3.57% | |
| LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -3.14% | -3.57% | |
| Form EFFECT LB PHARMACEUTICALS INC | SEC filing · Form EFFECT | SEC EDGAR | +0.27% | -2.81% | |
| LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB-102 with a Focus on Schizophrenia Treatment | Press release | GlobeNewswire | +0.27% | -2.81% | |
| Form POS AM LB PHARMACEUTICALS INC | SEC filing · Form POS | SEC EDGAR | -0.48% | -1.94% | |
| Form S-3ASR LB PHARMACEUTICALS INC | SEC filing · Form S-3ASR | SEC EDGAR | -0.48% | -1.94% | |
| Form 8-K LB PHARMACEUTICALS INC For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -4.01% | |
| LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer | Press release | GlobeNewswire | -1.29% | -4.01% | |
| Form 8-K LB PHARMACEUTICALS INC For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | -2.78% | |
| LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer | Press release | GlobeNewswire | -0.18% | -2.78% | |
| LB Pharmaceuticals to Participate in Upcoming September Investor Events | Press release | GlobeNewswire | +0.79% | +3.94% | |
| Form 10-Q LB PHARMACEUTICALS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.05% | -1.31% | |
| Form 8-K LB PHARMACEUTICALS INC For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -5.05% | -1.31% | |
| LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -5.05% | -1.31% | |
| Form 8-K LB PHARMACEUTICALS INC For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +4.60% | +10.98% | |
| LB Pharmaceuticals Announces $150 Million Private Placement | Press release | GlobeNewswire | +4.60% | +10.98% | |
| Form 8-K LB PHARMACEUTICALS INC For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +2.84% | +7.76% | |
| LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia | Press release | GlobeNewswire | +2.84% | +7.76% | |
| LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.61% | -1.56% | |
| LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations | Press release | GlobeNewswire | +0.26% | -1.41% | |
| Form 8-K LB PHARMACEUTICALS INC For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +2.40% | |
| Form 8-K LB PHARMACEUTICALS INC For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.01% | |
| LB Pharmaceuticals to Participate in Upcoming June Investor Events | Press release | GlobeNewswire | +6.76% | +1.64% | |
| Form 10-Q LB PHARMACEUTICALS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.67% | +4.97% | |
| Form 8-K LB PHARMACEUTICALS INC For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | +4.97% | |
| LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.67% | +4.97% | |
| Form ARS LB PHARMACEUTICALS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.26% | +0.69% | |
| Form DEF 14A LB PHARMACEUTICALS INC For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | +0.26% | +0.69% | |
| Form DEFA14A LB PHARMACEUTICALS INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.26% | +0.69% | |
| LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia | Press release | GlobeNewswire | +0.73% | -2.40% | |
| Form EFFECT LB PHARMACEUTICALS INC | SEC filing · Form EFFECT | SEC EDGAR | +0.06% | +10.35% | |
| LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -3.32% | -10.68% | |
| Form S-1 LB PHARMACEUTICALS INC | SEC filing · Form S-1 | SEC EDGAR | -0.07% | -6.54% | |
| LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) | Press release | GlobeNewswire | -1.01% | -3.25% | |
| Form 10-K LB PHARMACEUTICALS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.20% | -4.41% | |
| Form 8-K LB PHARMACEUTICALS INC For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | -4.41% | |
| Form S-8 LB PHARMACEUTICALS INC | SEC filing · Form S-8 | SEC EDGAR | +0.20% | -4.41% | |
| LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.20% | -4.41% | |
| LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia | Press release | GlobeNewswire | +1.28% | +2.93% | |
| Form 8-K LB PHARMACEUTICALS INC For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | -7.88% | |
| Form 8-K LB PHARMACEUTICALS INC For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | -2.79% | |
| LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors | Press release | GlobeNewswire | -2.39% | +3.93% | |
| LB Pharmaceuticals to Participate in Upcoming March Investor Events | Press release | GlobeNewswire | -1.86% | -2.56% | |
| LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -2.35% | |
| Form 8-K LB PHARMACEUTICALS INC For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | +6.61% | |
| LB Pharmaceuticals Announces $100.0 Million Private Placement | Press release | GlobeNewswire | -0.58% | +6.61% | |
| LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program | Press release | GlobeNewswire | -1.23% | -6.75% | |
| LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel | Press release | GlobeNewswire | +1.55% | +2.31% | |
| LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +1.91% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LBRX section they belong to.
Where else LBRX is measured.
LBRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is LB Pharmaceuticals Inc's median reaction calculated?
Every labeled LBRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 135 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 31% of LBRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LBRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.